Quick Takeaways
- SAMLYN CAPITAL, LLC filed SCHEDULE 13G/A for Corvus Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (CRVS).
- Disclosed ownership: 0%.
- Date of event: 30 Jun 2025.
SAMLYN CAPITAL, LLC - 30 Jun 2025 SCHEDULE 13G/A Report for Corvus Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (CRVS)
- Filing Manager
- SAMLYN CAPITAL, LLC
- Reporting Manager
- SAMLYN CAPITAL, LLC
- Symbol
- CRVS
- Disclosed Ownership
- 0 shares
- Ownership
- 0%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 13:32:57 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 15 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"SAMLYN CAPITAL, LLC disclosed 0% ownership in Corvus Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (CRVS) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 15 May 2025.
- Current filing was accepted on 14 Aug 2025, 13:32.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| SAMLYN CAPITAL, LLC | 0% | 0 | 0 | 0 | By: Samlyn, LP, its sole member, By: Samlyn GP, LLC, its general partner, By: /s/ Robert Pohly | Robert Pohly, Managing Member | |
| SAMLYN, LP | 0% | 0 | 0 | 0 | By: Samlyn GP, LLC, its general partner, By: /s/ Robert Pohly | Robert Pohly, Managing Member | |
| ROBERT POHLY | 0% | 0 | 0 | 0 | By: /s/ Robert Pohly | Robert Pohly |